Navigation Links
Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
Date:5/5/2009

CALGARY, May 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three-month period ended March 31, 2009.

"The first quarter of 2009 was highlighted by the announcement of very positive results in several of our combination REOLYSIN(R) clinical trials," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to report clinical benefit in the majority of patients treated with REOLYSIN in combination with chemotherapy or radiation, paving the way for our pivotal program to begin this year."

    Selected First Quarter Highlights:

    -  Announced positive interim results from a U.K. Phase I/II combination
       REOLYSIN and paclitaxel/carboplatin trial for patients with advanced
       head and neck cancers. Of 12 evaluable patients, five patients had
       partial responses (PR) and four patients had stable disease (SD), for
       a clinical benefit rate (complete response + partial response + stable
       disease) of 75%;

    -  Announced positive results from a U.K. combination REOLYSIN and
       docetaxel trial for patients with a variety of advanced cancers.
       Fifteen of the 17 evaluable patients experienced SD or better,
       including two PR, three minor responses and 10 SD, giving a clinical
       benefit rate of 88%;

    -  Completed enrolment in a U.K. combination REOLYSIN and gemcitabine
       clinical trial. Of the ten patients evaluable for response, two
       patients (breast and nasopharyngeal) had PRs and five patients had SD,
       for a clinical benefit rate of 70%;

    -  Started patient enrolment in a U.S. Phase 2 Combination REOLYSIN and
       paclitaxel/carboplatin clinical trial for patients with non-small cell
       lung cancer with K-RAS or EGFR-activated tumo
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
2. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
3. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
4. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
5. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
6. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
7. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
8. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
9. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
10. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
11. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 The Conferee Networking committee is ... Conferee Networking. These two-hour sessions provide a unique networking ... resolve problems, discuss new techniques, or brainstorm new ideas ... a topic for consideration is August 31, 2014, and ... Conferee Networking committee will review the topics, and status ...
(Date:7/25/2014)... 2014 At the request of the ... 60-day extension for the public comment period (Docket No. ... Model Aircraft established by Congress as part of the ... extension establishes the new deadline for comments as September ... Transportation/FAA notice published in the Federal Register on July ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2FAA Grants Comment Extension at the Request of AMA 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... INTRODUCTION , ... encoded bacterial enzymes which hydrolyze β -lactam antibiotics. The majority of ... One successful approach to combating the serine active site β -lactamases ... in combination with a β -lactam antibiotic 4 . , There ...
... , Evelyn McGown and Michael Su , ... fluorogenic oligonucleotide probes developed by Kramerand associates to detect ... They are single-stranded oligonucleotides that exist in a ... which bind together to form a stem. Thestrained loop ...
... , Anne T. Ferguson, Ph.D., ... , , INTRODUCTION , This ... XS from Molecular Devices to study the performance of the LIVE/DEAD ... two fluorescent dyes, calcein AM (cal AM) and ethidium homodimer (EthD-1), ...
Cached Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 2Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 3Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 2LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 3LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 5
(Date:7/25/2014)... associate professor of biomedical engineering at the University ... tissue engineering and artificial organ development., "Introduction to ... guide to entering into the field of artificial ... of biomedical engineering at UH, served as a ... while there are other published books on the ...
(Date:7/25/2014)... opened the way for the development of new lines of ... barley production is second only to wheat with 7-8 million ... important diseases of barley. , Senior Research Scientist Dr Alan ... on the cell walls of barley plants that block the ... by the ARC Centre of Excellence in Plant Cell Walls ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... effort to make data storage more cost-effective, a group of ... Karlsruhe Institute of Technology in Germany have created a DNA-based ... (UV) light to make it possible to encode information. The ... Applied Physics Letters , consists of a thin film of ...
... Athens, Ga. The knowledge that bacteria possess adaptable immune ... invaders is relatively new to science, and researchers across the ... to apply that knowledge in industry and medicine. ... how to harness this bacterial immune system to selectively target ...
... Ore. - Newly published research by scientists at Oregon ... how early embryonic stem cells develop and take part ... took place at OHSU,s Oregon National Primate Research Center, ... chimeric monkeys -- monkeys developed from stem cells taken ...
Cached Biology News:UGA scientists 'hijack' bacterial immune system 2UGA scientists 'hijack' bacterial immune system 3OHSU research produces the world's first primate chimeric offspring 2
activating transcription factor 4 (tax-responsive enhancer element B67),...
Request Info...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
Biology Products: